Synopsis– This is a research study to find out if K-877 (also called pemafibrate), the study drug, compared to placebo (a treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular (CV) complications (also referred to as “events”), such as heart attack, stroke, and death from these conditions, in adults with type-2 diabetes mellitus (T2D) who have elevated triglycerides (TGs; one type of fat), and low high-density lipoprotein cholesterol (HDL-C; “good” cholesterol).
Synopsis– The purpose of this study is to see if a high-dose influenza (“flu”) vaccine is able to safely reduce heart or lung-related problems compared to the standard-dose flu vaccine. Both the high dose and standard dose flu vaccines called Fluzone® are manufactured by Sanofi Pasteur.
Synopsis– Comparing two standard treatment options for people with advanced chronic kidney disease that have narrowed heart arteries due to the buildup of cholesterol to determine which one is the better and safer choice.
Synopsis– Studying new treatments for alcoholic hepatitis (AH) and investigating the pathophysiology (functional changes) of alcoholic hepatitis (liver inflammation caused by drinking alcohol). The primary purpose of this study is to determine whether treatment with pegfilgrastim (Neulasta®) in addition to prednisolone or pentoxifylline is more effective than treatment with prednisolone or pentoxifylline alone 06 in patients with AH.